ZyVersa Therapeutics, Inc. (ZVSA)

1.6399 +0.0299 (+1.86%) As of 10:57AM EDT. Market open.

ZyVersa Therapeutics, Inc.

2200 N. Commerce Parkway
Suite 208
Weston, FL 33326
United States
754 231 1688
https://www.zyversa.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 6

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Stephen C. Glover	Co-Founder, Chairman, CEO & Pres	450.5k	N/A	1960
Mr. Peter Wolfe	CFO & Sec.	275k	N/A	1968
Mr. Nicholas A. LaBella Jr., MS, RPh.	Chief Scientific Officer and Sr. VP of R&D	325k	N/A	1956
Ms. Karen A. Cashmere	Chief Commercial Officer	300k	N/A	1952
Ms. Melda Uzbil O'connell	Sr. VP of Corp. Devel.	N/A	N/A	N/A
Dr. Pablo A. Guzman FACC, M.D.	Chief Medical Officer, Sr. VP of Medical Affairs & Chairman of Renal Scientific Advisory Board	N/A	N/A	1950

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

Corporate Governance

ZyVersa Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.